成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 257933-82-7 Chemical Structure| 257933-82-7
Chemical Structure| 257933-82-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 257933-82-7

,{[proInfo.pro_purity]}

Pelitinib irreversiblly inhibits EGFR with IC50 of 38.5 nM.

Synonyms: EKB-569; WAY-EKB 569; WAY-172569

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Pelitinib

CAS No. :257933-82-7
Formula : C24H23ClFN5O2
M.W : 467.92
SMILES Code : O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(F)C(Cl)=C3)C2=C1)/C=C/CN(C)C
Synonyms :
EKB-569; WAY-EKB 569; WAY-172569
MDL No. :MFCD09837868
InChI Key :WVUNYSQLFKLYNI-AATRIKPKSA-N
Pubchem ID :6445562

Safety of Pelitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Pelitinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:38.5 nM

  • HER2/ErbB2

    ErbB2, IC50:1.255 μM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
HEK293 1, 2, 5 μM 3 h To study the inhibition kinetics of pelitinib on ABCB1- and ABCG2-mediated topotecan efflux. Results showed that pelitinib is a competitive inhibitor of both ABCB1 and ABCG2. PMC4543615
A549 3 μM 48 h To evaluate the effect of pelitinib in combination with topotecan on apoptosis in A549 cells after hyperthermia exposure. Results showed that pelitinib significantly enhanced the apoptotic effect of topotecan after hyperthermia. PMC4543615
Mouse tracheal epithelial cells 50 μM 7 days To study the effect of PI3K inhibitor on the survival of ciliated epithelial cells, results showed that PI3K inhibitor induced apoptosis of ciliated cells. PMC1359039
Mouse tracheal epithelial cells 0.3 μM 7 days To study the effect of EKB-569 on the survival of ciliated epithelial cells, results showed that EKB-569 induced apoptosis of ciliated cells. PMC1359039
SNU449 cells 0.2, 0.5, 1, 2 μM 48 h To evaluate the inhibitory effect of EKB-569 on the migration of SNU449 cells. The results showed that EKB-569 significantly inhibited wound healing of SNU449 cells. PMC10373356
Hep3B cells 0.2, 0.5, 1, 2 μM 48 h To evaluate the inhibitory effect of EKB-569 on the migration of Hep3B cells. The results showed that EKB-569 significantly inhibited wound healing of Hep3B cells. PMC10373356
Huh7 cells 0.2, 0.5, 1, 2 μM 48 h To evaluate the inhibitory effect of EKB-569 on the migration and invasion of Huh7 cells. The results showed that EKB-569 significantly inhibited wound healing and invasion of Huh7 cells, and reduced the activities of MMP-2 and MMP-9. PMC10373356

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mice Virus-induced airway epithelial remodeling model Orally 20 mg/kg Once daily for 11 days To study the effect of EKB-569 on virus-induced epithelial remodeling, results showed that EKB-569 prevented increases in ciliated and goblet cells. PMC1359039
BALB/c mice 4T1 tumor model Oral 5 mg/kg, 10 mg/kg, 20 mg/kg Once daily for 14 days To evaluate the anti-tumor effects of pelitinib in the 4T1 tumor model, results showed that pelitinib significantly inhibited tumor volume and weight, and suppressed M2 macrophage polarization and the EMT process PMC11388705
C57BL/6J mice Wild-type mice Oral 150 mg/kg of food Daily for 90 days To evaluate the effects of EKB-569 on cardiac function and pathology. Results showed that EKB-569 caused loss, thinning of the left ventricular wall, changes in cardiac function, and increased cardiac fibrosis and apoptotic cell numbers. PMC2683406

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00072748 Colorectal Neoplasms|Colonic N... More >>eoplasms|Rectal Neoplasms Less << PHASE2 COMPLETED 2025-10-04 -
NCT00098501 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00067548 Non-Small-Cell Lung Carcinoma|... More >>Carcinoma, Non-Small Cell Lung|Lung Neoplasms Less << PHASE2 COMPLETED 2025-01-05 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.69mL

2.14mL

1.07mL

21.37mL

4.27mL

2.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories